Rajiv R. Srivastava

FDA investigator

Appears on 30 documents from 2018 to 2025, mostly at sites in India. Most often cites production record review (21 CFR 211.192).

30
Documents on file
4.8
Observations per 483
2018
First seen
2025
Most recent

What they cite most

From 145 observations

Activity by year

2018: 5, 2019: 6, 2020: 1, 2022: 4, 2023: 7, 2024: 4, 2025: 3

Where

India 19 · New York 4 · South Korea 2 · China 1 · France 1 · Italy 1

Is Rajiv R. Srivastava coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

30 documents, newest first
FirmOpen
483 Dr. Reddy’s Laboratories LimitedDec 12, 2025 · Srikakulam, India
483 UB I Phar ma IncOct 14, 2025 · Hsinchu, Taiwan
483 Orchid Pharma LimitedFeb 18, 2025 · Alathur, India
483 Samsung Bioepis Co. LtdNov 22, 2024 · Incheon, South Korea
483 Janssen Vaccines CorporationNov 19, 2024 · Incheon, South Korea
483 AARTI DRUGS LTDSep 20, 2024 · Tarapur, India
483 Chinese Peptide CompanyJun 14, 2024 · Hangzhou, China

About this profile

What does Rajiv R. Srivastava inspect?

Rajiv R. Srivastava appears on 30 documents on file covering 29 sites, mostly in India.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.67 and 21 CFR 211.22.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Rajiv R. Srivastava is dated Dec 12, 2025.